Multi-omics Dissection of Gut Microbiome Engraftment During FMT
Starting soon · Not applicable
Conditions studied: Recurrent C. Difficile (rCDI), Ulcerative Colitis (UC), Metabolic Syndrome (MetS)
In brief
The gut microbiota plays a key role in immunity and metabolism and contributes to diseases such as recurrent C. difficile infection (rCDI), ulcerative colitis (UC), and metabolic syndrome (MetS). Microbiota therapeutics, particularly fecal microbiota transplantation (FMT), show promise-achieving \~90% cure rates in rCDI-but demonstrate variable efficacy in chronic conditions. Microbiome engraftment appears critical for FMT success, yet consistent predictors remain lacking. A meta-analysis of 20 FMT studies by our group and the Segata Lab linked engraftment to clinical response across diseases, with taxon-specific patterns and ML-based predictability. While viral, fungal, host immune, genetic, and metabolic factors may affect engraftment, their roles are not well-defined. Key unresolved questions include the interplay among host factors, microbial strains, and metabolites, their influence on engraftment, and impact on clinical outcomes. This study aims to unravel microbiome engraftment dynamics and link them to therapeutic response.
Key facts
- Study ID
- NCT06992453
- Run by
- Catholic University of the Sacred Heart
- People needed
- 90
- Starts
- 2026-04-23
- Expected to finish
- 2029-02-19
- Last updated by the study team
- 2026-04-28
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Coorte: Patients affected by Ulcerative Colitis
- Age ≥18 years.
- UC with mild-to-moderate activity (total Mayo score 3-10 + endoscopic subscore≥1) (23)
- UC during stable maintenance therapy (> 8 weeks with salicylates, immunosuppressants);
- Ability to give informed consent.
- Coorte: Patients affected by metabolic syndrome
- Age ≥18 years.
- Patients with MetS (high glycaemia levels (> 100 mg/dL), hypertension (> 130/85 mmHg), raised triglyceride levels (> 150 mg/dL), low high-density lipoprotein cholesterol levels (< 40 mg/dL in men; <50 mg/dL in women), and abdominal obesity (waist circumference of > 102 cm in men; >88 cm in women)
- Stable treatment (> 8 weeks) of one of these disorders, included in MetS definition.
- Ability to give informed consent
- Coorte: Patients affected by rCDI
- Age ≥18 years
- Mild recurrent Clostridioides difficile infection (26)
- Ability to give informed consent.
You may not qualify if…
- Pregnancy, breastfeeding, and the refusal to follow an effective contraception method for all the study duration (for women).
- Known active gastrointestinal disorders (e.g. infectious gastroenteritis except CDI, coeliac disease, irritable bowel syndrome, chronic pancreatitis, biliary salt diarrhoea) apart from UC, with clinical characteristics reports in inclusion criteria.
- Antimicrobial treatment up to 4 weeks prior to screening visit (apart for patients with rCDI)
- Previous colorectal surgery or cutaneous stoma
- Critical and severe comorbidities
- Inability to give informed consent.
Where it is running
- Catholic University of the Sacred Heart — Rome, RM, Italy
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.